Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Shares Outstanding (Weighted Average) (2019 - 2025)

Historic Shares Outstanding (Weighted Average) for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $222.0 million.

  • Allogene Therapeutics' Shares Outstanding (Weighted Average) rose 614.28% to $222.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $222.0 million, marking a year-over-year increase of 614.28%. This contributed to the annual value of $194.8 million for FY2024, which is 2413.79% up from last year.
  • Per Allogene Therapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $222.0 million for Q3 2025, which was up 614.28% from $218.9 million recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' Shares Outstanding (Weighted Average) registered a high of $222.0 million during Q3 2025, and its lowest value of $132.2 million during Q1 2021.
  • In the last 5 years, Allogene Therapeutics' Shares Outstanding (Weighted Average) had a median value of $146.8 million in 2023 and averaged $165.6 million.
  • As far as peak fluctuations go, Allogene Therapeutics' Shares Outstanding (Weighted Average) soared by 226.91% in 2023, and later soared by 2944.96% in 2024.
  • Allogene Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $135.8 million in 2021, then increased by 5.39% to $143.1 million in 2022, then increased by 9.63% to $156.9 million in 2023, then grew by 24.14% to $194.8 million in 2024, then increased by 13.98% to $222.0 million in 2025.
  • Its last three reported values are $222.0 million in Q3 2025, $218.9 million for Q2 2025, and $215.4 million during Q1 2025.